- Home
- LSB
LSB
LAKESHORE BIOPHARMA CO LTD
as 03-28-2025 1:06pm EST
Stocks
| Founded: | 2002 | Country: | China |
| Employees: | N/A | City: | N/A |
| Market Cap: | N/A | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 15.4K |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -5.61 | EPS Growth: | N/A |
| 52 Week Low/High: | $1.81 - $11.20 | Next Earning Date: | 12-19-2024 |
| Revenue: | $79,415,311 | Revenue Growth: | -16.56% |
| Revenue Growth (this year): | 39.33% | Revenue Growth (next year): | 75.61% |
Latest LAKESHORE BIOPHARMA CO LTD News
LSB Breaking Stock News: Dive into LSB Ticker-Specific Updates for Smart Investing
PR Newswire
3 months ago
LakeShore Biopharma Reports Unaudited Financial Results for the First Half of Fiscal Year 2025 and Updates Full-Year Guidance
GlobeNewswire
4 months ago
LakeShore Biopharma Provides Update on Ongoing Criminal Investigation Involving Former Chairman in China
GlobeNewswire
5 months ago
LakeShore Biopharma Initiates Biologics License Application of PIKA Rabies Vaccine to the Drug Regulatory Authority of Pakistan
PR Newswire
5 months ago
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
PR Newswire
5 months ago
LakeShore Biopharma Regains Compliance with Nasdaq Minimum Bid Price Requirement
TipRanks
5 months ago
LakeShore Biopharma Advances with Rabies Vaccine Trial
PR Newswire
5 months ago
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
PR Newswire
5 months ago
LakeShore Biopharma Granted Phase III Clinical Trial Approval to Explore Simplified Regimens for YSJA Rabies Vaccine
Compare LSB vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "LSB LAKESHORE BIOPHARMA CO LTD - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.